Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cingulate Inc ( (CING) ) has shared an update.
On September 25, 2025, Cingulate Inc. held a Special Meeting of Stockholders where two proposals were presented. The first proposal, concerning the issuance of more than 20% of the company’s common stock in accordance with a purchase agreement with Lincoln Park Capital Fund, LLC, was approved. The second proposal, which allowed for the adjournment of the meeting if necessary, was also approved but deemed unnecessary as there were sufficient votes to approve the first proposal.
The most recent analyst rating on (CING) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 141,897
Technical Sentiment Signal: Sell
Current Market Cap: $20.73M
See more data about CING stock on TipRanks’ Stock Analysis page.